Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
Sébert M, Freiman L, Chaffaut C, Guerci A, Peterlin P, Thépot S, Beyne-Rauzy O, Park S, Cluzeau T, Chermat F, Fenaux P, Preudhomme C, Clappier E, Chevret S, Adès L, Duployez N, Duchmann M.
Sébert M, et al. Among authors: preudhomme c.
Leukemia. 2024 Apr;38(4):918-922. doi: 10.1038/s41375-024-02180-3. Epub 2024 Feb 17.
Leukemia. 2024.
PMID: 38368440
No abstract available.